HEALTH

J.P. Borneman named chairman of CHPA’s political action committee

BY Michael Johnsen

WASHINGTON The Consumer Healthcare Products Association’s political action committee recently named J.P. Borneman, chairman and chief executive officer of Hyland’s, as chairman of the CHPA-PAC.

Since becoming a member of CHPA, Borneman has been a leading supporter of the CHPA-PAC. As chair, he will serve as CHPA-PAC’s liaison to the association’s board of directors on all political action committee matters.

The CHPA-PAC is the nonpartisan political action committee funded by voluntary individual contributions. CHPA-PAC supports congressional candidates who will advance quality healthcare.

There has been an unprecedented level of congressional attention to issues affecting the OTC industry of late, including the import-safety legislation, merchandising restrictions on products containing pseudoephedrine or dextromethorphan and the debate over whether or not cough/cold medicines ought to be marketed for use in children under the age of six.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Berkeley Premium Nutraceuticals founder sentenced to prison for money laundering

BY Michael Johnsen

CINCINNATI Steve Warshak, founder of Berkeley Premium Nutraceuticals, which distributed the sexual enhancement supplement Enzyte, was sentenced to 25 years in prison last week and fined an additional $93,000 for fraud and money laundering, according to a report in USA Today.

In addition, U.S. District Judge Arthur Spiegel ordered Warshak and several of his associates to forfeit more than $500 million.

Berkeley Premium Nutraceuticals promoted its product heavily on television in the direct-to-consumer channel.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

DRJ announces sales increased 31 percent for FY 2008

BY Michael Johnsen

ENCINITAS, Calif. DRJ Group Inc., the makers of Stopain topical analgesics, on Thursday announced that sales increased 31 percent overall during its fiscal year 2008 ending June 30.

The most dramatic growth was in the grocery and health food category, which grew by 69 percent.

“We made some great enhancements to Stopain during the past 12 months,” stated Bob Miller, president and chief executive officer of DRJ. “This included adding our new, patented cream formula; improving on-shelf visibility with easy-to-read packaging; and widening the availability of our Stopain product family through increased distribution at some of the country’s major retailers and on our brand’s web site.”

Earlier this year, Meijer supercenters throughout Michigan, Indiana, Illinois, Ohio and Kentucky began carrying Stopain products. In May, the sale of Stopain Spray and Roll-on began in Wal-Mart locations throughout the United States, the company stated.

The Emerson Group, a national sales organization that represents DRJ Group, reports that Stopain experienced one of the largest sales percentage increases of any of its clients during fiscal year 2008.

Stopain products include the company’s new patented cream formula, as well as spray and roll-on SKUs.

Stopain can be purchased nationally in over 25,000 independent pharmacies and national chain drug stores, including Walgreens, Wal-Mart, CVS and Rite-Aid.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?